Shares of Questcor closed down 7% today, after Blue Cross Blue Shield Michigan came out against Acthar Gel in all indications except for infantile spasm. In this video, Motley Fool health-care analyst David Williamson dives into today's news, and explains what it means for investors going forward.
Questcor is one of the most debated names in all of biotech. Its premium-priced drug, Acthar, is growing at a torrid pace -- and minting money in the process. However, recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.
The article Questcor Gets Hit Again originally appeared on Fool.com.David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.